Which has stronger earnings and valuation, MRNA or OCGN?

Ocugen has lower revenue, but higher earnings than Moderna. Moderna is trading at a lower price-to-earnings ratio than Ocugen, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Moderna $1.94B 39.02 -$2.82B -$7.99 N/A Ocugen $4.41M 78.43 -$67.85M -$0.26 N/A

Is MRNA or OCGN more profitable?

Ocugen has a net margin of 0.00% compared to Moderna's net margin of -141.43%. Moderna's return on equity of -28.30% beat Ocugen's return on equity. Company Net Margins Return on Equity Return on Assets Moderna -141.43% -28.30% -19.39% Ocugen N/A -127,987.80% -115.95%

Does the media prefer MRNA or OCGN?

In the previous week, Moderna had 20 more articles in the media than Ocugen. MarketBeat recorded 40 mentions for Moderna and 20 mentions for Ocugen. Ocugen's average media sentiment score of 0.74 beat Moderna's score of 0.27 indicating that Ocugen is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Moderna 7 Very Positive mention(s) 15 Positive mention(s) 8 Neutral mention(s) 9 Negative mention(s) 1 Very Negative mention(s) Neutral Ocugen 5 Very Positive mention(s) 0 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has higher earnings and valuation, PFE or OCGN?

Pfizer has higher revenue and earnings than Ocugen. Ocugen is trading at a lower price-to-earnings ratio than Pfizer, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Pfizer $62.58B 2.53 $7.77B $0.76 36.59 Ocugen $4.41M 78.43 -$67.85M -$0.26 N/A

Is PFE or OCGN more profitable?

Pfizer has a net margin of 6.80% compared to Ocugen's net margin of 0.00%. Pfizer's return on equity of 19.63% beat Ocugen's return on equity. Company Net Margins Return on Equity Return on Assets Pfizer 6.80% 19.63% 8.46% Ocugen N/A -127,987.80% -115.95%

Does the media favor PFE or OCGN?

In the previous week, Pfizer had 27 more articles in the media than Ocugen. MarketBeat recorded 47 mentions for Pfizer and 20 mentions for Ocugen. Ocugen's average media sentiment score of 0.74 beat Pfizer's score of 0.42 indicating that Ocugen is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Pfizer 18 Very Positive mention(s) 10 Positive mention(s) 10 Neutral mention(s) 4 Negative mention(s) 5 Very Negative mention(s) Neutral Ocugen 5 Very Positive mention(s) 0 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer OCGN or RARE?

In the previous week, Ocugen had 12 more articles in the media than Ultragenyx Pharmaceutical. MarketBeat recorded 20 mentions for Ocugen and 8 mentions for Ultragenyx Pharmaceutical. Ocugen's average media sentiment score of 0.74 beat Ultragenyx Pharmaceutical's score of 0.35 indicating that Ocugen is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Ocugen 5 Very Positive mention(s) 0 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Ultragenyx Pharmaceutical 1 Very Positive mention(s) 2 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Is AVBP or OCGN more profitable?

ArriVent BioPharma's return on equity of -50.26% beat Ocugen's return on equity. Company Net Margins Return on Equity Return on Assets ArriVent BioPharma N/A -50.26% -46.66% Ocugen N/A -127,987.80% -115.95%

Does the media favor AVBP or OCGN?

In the previous week, Ocugen had 19 more articles in the media than ArriVent BioPharma. MarketBeat recorded 20 mentions for Ocugen and 1 mentions for ArriVent BioPharma. ArriVent BioPharma's average media sentiment score of 0.90 beat Ocugen's score of 0.74 indicating that ArriVent BioPharma is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ArriVent BioPharma 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Ocugen 5 Very Positive mention(s) 0 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has better valuation and earnings, AAPG or OCGN?

Ocugen has lower revenue, but higher earnings than Ascentage Pharma Group International. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Ascentage Pharma Group International $82.10M 17.47 -$177.71M N/A N/A Ocugen $4.41M 78.43 -$67.85M -$0.26 N/A

Is AAPG or OCGN more profitable?

Ascentage Pharma Group International's return on equity of 0.00% beat Ocugen's return on equity. Company Net Margins Return on Equity Return on Assets Ascentage Pharma Group International N/A N/A N/A Ocugen N/A -127,987.80% -115.95%

Does the media prefer AAPG or OCGN?

In the previous week, Ocugen had 19 more articles in the media than Ascentage Pharma Group International. MarketBeat recorded 20 mentions for Ocugen and 1 mentions for Ascentage Pharma Group International. Ocugen's average media sentiment score of 0.74 beat Ascentage Pharma Group International's score of -0.63 indicating that Ocugen is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Ascentage Pharma Group International 0 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Negative Ocugen 5 Very Positive mention(s) 0 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Ocugen (OCGN) Competitors

$1.02 +0.02 (+2.00%)

Closing price 10/2/2026 04:00 PM Eastern

Extended Trading

$1.01 -0.01 (-0.49%)

As of 10/2/2026 07:58 PM Eastern

Compare

OCGN vs. MRNA, PFE, RARE, AVBP, and AAPG

Should you buy Ocugen stock or one of its competitors? Ocugen's main competitors and comparable companies include Moderna (MRNA), Pfizer (PFE), Ultragenyx Pharmaceutical (RARE), ArriVent BioPharma (AVBP), and Ascentage Pharma Group International (AAPG). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare" sector.

How does Ocugen compare to Moderna?

Moderna (NASDAQ:MRNA) and Ocugen (NASDAQ:OCGN) are both healthcare companies, but which is the better business? We will compare the two companies based on the strength of their dividends, institutional ownership, profitability, media sentiment, analyst recommendations, earnings, valuation and risk.

Ocugen has lower revenue, but higher earnings than Moderna. Moderna is trading at a lower price-to-earnings ratio than Ocugen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Moderna	$1.94B	39.02	-$2.82B	-$7.99	N/A
Ocugen	$4.41M	78.43	-$67.85M	-$0.26	N/A

Moderna currently has a consensus price target of $77.83, suggesting a potential downside of 59.04%. Ocugen has a consensus price target of $9.50, suggesting a potential upside of 831.37%. Given Ocugen's stronger consensus rating and higher possible upside, analysts clearly believe Ocugen is more favorable than Moderna.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Moderna	5 Sell rating(s)	13 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.08
Ocugen	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60

Ocugen has a net margin of 0.00% compared to Moderna's net margin of -141.43%. Moderna's return on equity of -28.30% beat Ocugen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Moderna	-141.43%	-28.30%	-19.39%
Ocugen	N/A	-127,987.80%	-115.95%

75.3% of Moderna shares are owned by institutional investors. Comparatively, 10.3% of Ocugen shares are owned by institutional investors. 10.8% of Moderna shares are owned by insiders. Comparatively, 4.0% of Ocugen shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

In the previous week, Moderna had 20 more articles in the media than Ocugen. MarketBeat recorded 40 mentions for Moderna and 20 mentions for Ocugen. Ocugen's average media sentiment score of 0.74 beat Moderna's score of 0.27 indicating that Ocugen is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Moderna	7 Very Positive mention(s)	15 Positive mention(s)	8 Neutral mention(s)	9 Negative mention(s)	1 Very Negative mention(s)	Neutral
Ocugen	5 Very Positive mention(s)	0 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Moderna has a beta of 1.09, suggesting that its share price is 9% more volatile than the broader market. Comparatively, Ocugen has a beta of 2.27, suggesting that its share price is 127% more volatile than the broader market.

Summary

Ocugen beats Moderna on 9 of the 16 factors compared between the two stocks.

How does Ocugen compare to Pfizer?

Pfizer (NYSE:PFE) and Ocugen (NASDAQ:OCGN) are both healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, dividends, earnings, media sentiment, risk, institutional ownership, profitability and analyst recommendations.

68.4% of Pfizer shares are owned by institutional investors. Comparatively, 10.3% of Ocugen shares are owned by institutional investors. 0.6% of Pfizer shares are owned by insiders. Comparatively, 4.0% of Ocugen shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Pfizer has a net margin of 6.80% compared to Ocugen's net margin of 0.00%. Pfizer's return on equity of 19.63% beat Ocugen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Pfizer	6.80%	19.63%	8.46%
Ocugen	N/A	-127,987.80%	-115.95%

In the previous week, Pfizer had 27 more articles in the media than Ocugen. MarketBeat recorded 47 mentions for Pfizer and 20 mentions for Ocugen. Ocugen's average media sentiment score of 0.74 beat Pfizer's score of 0.42 indicating that Ocugen is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Pfizer	18 Very Positive mention(s)	10 Positive mention(s)	10 Neutral mention(s)	4 Negative mention(s)	5 Very Negative mention(s)	Neutral
Ocugen	5 Very Positive mention(s)	0 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Pfizer has higher revenue and earnings than Ocugen. Ocugen is trading at a lower price-to-earnings ratio than Pfizer, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pfizer	$62.58B	2.53	$7.77B	$0.76	36.59
Ocugen	$4.41M	78.43	-$67.85M	-$0.26	N/A

Pfizer has a beta of 0.32, suggesting that its stock price is 68% less volatile than the broader market. Comparatively, Ocugen has a beta of 2.27, suggesting that its stock price is 127% more volatile than the broader market.

Pfizer currently has a consensus price target of $28.39, indicating a potential upside of 2.09%. Ocugen has a consensus price target of $9.50, indicating a potential upside of 831.37%. Given Ocugen's stronger consensus rating and higher possible upside, analysts clearly believe Ocugen is more favorable than Pfizer.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pfizer	2 Sell rating(s)	14 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.19
Ocugen	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60

Summary

Pfizer beats Ocugen on 10 of the 16 factors compared between the two stocks.

How does Ocugen compare to Ultragenyx Pharmaceutical?

Ocugen (NASDAQ:OCGN) and Ultragenyx Pharmaceutical (NASDAQ:RARE) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, valuation, risk, profitability, media sentiment, analyst recommendations, earnings and institutional ownership.

Ocugen currently has a consensus target price of $9.50, suggesting a potential upside of 831.37%. Ultragenyx Pharmaceutical has a consensus target price of $34.58, suggesting a potential upside of 127.19%. Given Ocugen's stronger consensus rating and higher probable upside, analysts clearly believe Ocugen is more favorable than Ultragenyx Pharmaceutical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ocugen	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60
Ultragenyx Pharmaceutical	1 Sell rating(s)	10 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.48

Ocugen has a beta of 2.27, indicating that its stock price is 127% more volatile than the broader market. Comparatively, Ultragenyx Pharmaceutical has a beta of 0.35, indicating that its stock price is 65% less volatile than the broader market.

10.3% of Ocugen shares are owned by institutional investors. Comparatively, 97.7% of Ultragenyx Pharmaceutical shares are owned by institutional investors. 4.0% of Ocugen shares are owned by company insiders. Comparatively, 5.2% of Ultragenyx Pharmaceutical shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Ocugen has higher earnings, but lower revenue than Ultragenyx Pharmaceutical. Ocugen is trading at a lower price-to-earnings ratio than Ultragenyx Pharmaceutical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ocugen	$4.41M	78.43	-$67.85M	-$0.26	N/A
Ultragenyx Pharmaceutical	$717M	2.09	-$575M	-$5.84	N/A

Ocugen has a net margin of 0.00% compared to Ultragenyx Pharmaceutical's net margin of -81.79%. Ultragenyx Pharmaceutical's return on equity of 0.00% beat Ocugen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ocugen	N/A	-127,987.80%	-115.95%
Ultragenyx Pharmaceutical	-81.79%	N/A	-44.40%

In the previous week, Ocugen had 12 more articles in the media than Ultragenyx Pharmaceutical. MarketBeat recorded 20 mentions for Ocugen and 8 mentions for Ultragenyx Pharmaceutical. Ocugen's average media sentiment score of 0.74 beat Ultragenyx Pharmaceutical's score of 0.35 indicating that Ocugen is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Ocugen	5 Very Positive mention(s)	0 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Ultragenyx Pharmaceutical	1 Very Positive mention(s)	2 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Ocugen beats Ultragenyx Pharmaceutical on 9 of the 17 factors compared between the two stocks.

How does Ocugen compare to ArriVent BioPharma?

ArriVent BioPharma (NASDAQ:AVBP) and Ocugen (NASDAQ:OCGN) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their profitability, dividends, earnings, risk, media sentiment, valuation, analyst recommendations and institutional ownership.

ArriVent BioPharma has a beta of 1.34, meaning that its stock price is 34% more volatile than the broader market. Comparatively, Ocugen has a beta of 2.27, meaning that its stock price is 127% more volatile than the broader market.

ArriVent BioPharma's return on equity of -50.26% beat Ocugen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ArriVent BioPharma	N/A	-50.26%	-46.66%
Ocugen	N/A	-127,987.80%	-115.95%

In the previous week, Ocugen had 19 more articles in the media than ArriVent BioPharma. MarketBeat recorded 20 mentions for Ocugen and 1 mentions for ArriVent BioPharma. ArriVent BioPharma's average media sentiment score of 0.90 beat Ocugen's score of 0.74 indicating that ArriVent BioPharma is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ArriVent BioPharma	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Ocugen	5 Very Positive mention(s)	0 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

9.5% of ArriVent BioPharma shares are held by institutional investors. Comparatively, 10.3% of Ocugen shares are held by institutional investors. 8.6% of ArriVent BioPharma shares are held by insiders. Comparatively, 4.0% of Ocugen shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Ocugen has higher revenue and earnings than ArriVent BioPharma. ArriVent BioPharma is trading at a lower price-to-earnings ratio than Ocugen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ArriVent BioPharma	N/A	N/A	-$166.31M	-$3.62	N/A
Ocugen	$4.41M	78.43	-$67.85M	-$0.26	N/A

ArriVent BioPharma currently has a consensus price target of $44.86, indicating a potential upside of 58.67%. Ocugen has a consensus price target of $9.50, indicating a potential upside of 831.37%. Given Ocugen's higher possible upside, analysts plainly believe Ocugen is more favorable than ArriVent BioPharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ArriVent BioPharma	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.70
Ocugen	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60

Summary

Ocugen beats ArriVent BioPharma on 8 of the 14 factors compared between the two stocks.

How does Ocugen compare to Ascentage Pharma Group International?

Ascentage Pharma Group International (NASDAQ:AAPG) and Ocugen (NASDAQ:OCGN) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their media sentiment, analyst recommendations, profitability, earnings, risk, institutional ownership, dividends and valuation.

10.3% of Ocugen shares are held by institutional investors. 4.0% of Ocugen shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Ascentage Pharma Group International currently has a consensus price target of $46.43, indicating a potential upside of 202.27%. Ocugen has a consensus price target of $9.50, indicating a potential upside of 831.37%. Given Ocugen's higher possible upside, analysts clearly believe Ocugen is more favorable than Ascentage Pharma Group International.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ascentage Pharma Group International	0 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	2 Strong Buy rating(s)	3.20
Ocugen	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60

Ascentage Pharma Group International has a beta of 0.12, suggesting that its share price is 88% less volatile than the broader market. Comparatively, Ocugen has a beta of 2.27, suggesting that its share price is 127% more volatile than the broader market.

Ocugen has lower revenue, but higher earnings than Ascentage Pharma Group International.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ascentage Pharma Group International	$82.10M	17.47	-$177.71M	N/A	N/A
Ocugen	$4.41M	78.43	-$67.85M	-$0.26	N/A

In the previous week, Ocugen had 19 more articles in the media than Ascentage Pharma Group International. MarketBeat recorded 20 mentions for Ocugen and 1 mentions for Ascentage Pharma Group International. Ocugen's average media sentiment score of 0.74 beat Ascentage Pharma Group International's score of -0.63 indicating that Ocugen is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Ascentage Pharma Group International	0 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Negative
Ocugen	5 Very Positive mention(s)	0 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Ascentage Pharma Group International's return on equity of 0.00% beat Ocugen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ascentage Pharma Group International	N/A	N/A	N/A
Ocugen	N/A	-127,987.80%	-115.95%

Summary

Ocugen beats Ascentage Pharma Group International on 8 of the 14 factors compared between the two stocks.

Get Ocugen News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding OCGN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

OCGN vs. The Competition

Export

Metric	Ocugen	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$345.89M	$3.87B	$7.14B	$13.22B
Dividend Yield	N/A	3.64%	2.53%	16.78%
P/E Ratio	N/A	13.13	275.97	26.04
Price / Sales	78.43	1,430.61	672.86	109.50
Price / Cash	N/A	122.60	77.60	51.75
Price / Book	-25.50	16.63	10.93	6.31
Net Income	-$67.85M	-$22.71M	$3.51B	$362.16M
7 Day Performance	N/A	-2.99%	-2.00%	-1.66%
1 Month Performance	-24.44%	-10.60%	-6.15%	-4.50%
1 Year Performance	-42.37%	19.44%	7.44%	2.06%

Ocugen Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
OCGN Ocugen	1.7617 of 5 stars	$1.02 +2.0%	$9.50 +831.4%	-42.4%	$345.89M	$4.41M	N/A	116	News Coverage Analyst Upgrade Analyst Revision Gap Up
MRNA Moderna	1.9454 of 5 stars	$172.94 +12.3%	$76.72 -55.6%	+569.8%	$61.50B	$1.94B	N/A	4,700	Trending News Analyst Downgrade
PFE Pfizer	2.8789 of 5 stars	$27.77 +0.4%	$28.39 +2.2%	+2.7%	$157.65B	$62.58B	36.54	75,000	Trending News
RARE Ultragenyx Pharmaceutical	3.5759 of 5 stars	$14.65 +1.0%	$34.58 +136.0%	-50.7%	$1.43B	$673M	N/A	1,371
AVBP ArriVent BioPharma	2.6803 of 5 stars	$29.74 +2.9%	$44.86 +50.8%	+50.1%	$1.42B	N/A	N/A	77	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:OCGN) was last updated on 10/3/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Ocugen (OCGN) Competitors

OCGN vs. MRNA, PFE, RARE, AVBP, and AAPG

How does Ocugen compare to Moderna?

Summary

How does Ocugen compare to Pfizer?

Summary

How does Ocugen compare to Ultragenyx Pharmaceutical?

Summary

How does Ocugen compare to ArriVent BioPharma?

Summary

How does Ocugen compare to Ascentage Pharma Group International?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

OCGN vs. The Competition

Ocugen Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Ocugen (OCGN) Competitors

OCGN vs. MRNA, PFE, RARE, AVBP, and AAPG

How does Ocugen compare to Moderna?

Which has stronger earnings and valuation, MRNA or OCGN?

Do analysts rate MRNA or OCGN?

Is MRNA or OCGN more profitable?

Do institutionals and insiders have more ownership in MRNA or OCGN?

Does the media prefer MRNA or OCGN?

Which has more risk and volatility, MRNA or OCGN?

Summary

How does Ocugen compare to Pfizer?

Do institutionals & insiders hold more shares of PFE or OCGN?

Is PFE or OCGN more profitable?

Does the media favor PFE or OCGN?

Which has higher earnings and valuation, PFE or OCGN?

Which has more risk & volatility, PFE or OCGN?

Do analysts rate PFE or OCGN?

Summary

How does Ocugen compare to Ultragenyx Pharmaceutical?

Do analysts recommend OCGN or RARE?

Which has more volatility & risk, OCGN or RARE?

Do institutionals and insiders hold more shares of OCGN or RARE?

Which has better earnings and valuation, OCGN or RARE?

Is OCGN or RARE more profitable?

Does the media prefer OCGN or RARE?

Summary

How does Ocugen compare to ArriVent BioPharma?

Which has more volatility & risk, AVBP or OCGN?

Is AVBP or OCGN more profitable?

Does the media favor AVBP or OCGN?

Do insiders and institutionals hold more shares of AVBP or OCGN?

Which has preferable valuation & earnings, AVBP or OCGN?

Do analysts prefer AVBP or OCGN?

Summary

How does Ocugen compare to Ascentage Pharma Group International?

Do insiders & institutionals believe in AAPG or OCGN?

Do analysts rate AAPG or OCGN?

Which has more risk and volatility, AAPG or OCGN?

Which has better valuation and earnings, AAPG or OCGN?

Does the media prefer AAPG or OCGN?

Is AAPG or OCGN more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

OCGN vs. The Competition

Ocugen Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools